Egyszerű nézet

dc.contributor.author Hajosi-Kalcakosz S
dc.contributor.author Dezső, Katalin
dc.contributor.author Bugyik, Edina
dc.contributor.author Bödör, Csaba
dc.contributor.author Paku, Sándor
dc.contributor.author Pavai Z
dc.contributor.author Halász, Judit
dc.contributor.author Schlachter, Krisztina
dc.contributor.author Schaff, Zsuzsa
dc.contributor.author Nagy, Péter
dc.date.accessioned 2018-06-18T12:46:22Z
dc.date.available 2018-06-18T12:46:22Z
dc.date.issued 2012
dc.identifier 84865986831
dc.identifier.citation pagination=86, pages: 7; journalVolume=7; journalTitle=DIAGNOSTIC PATHOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/5621
dc.identifier.uri doi:10.1186/1746-1596-7-86
dc.description.abstract BACKGROUND: The immunohistochemical demonstration of Enhancer of zeste homologue 2 (EZH2) proved to be a useful marker in several tumor types. It has been described to distinguish reliably hepatocellular carcinomas from liver adenomas and other benign hepatocellular lesions. However, no other types of malignant liver tumors were studied so far. METHODS: To evaluate the diagnostic value of this protein in hepatic tumors we have investigated the presence of EZH2 by immunohistochemistry in hepatocellular carcinomas and other common hepatic tumors.EZH2 expression was examined in 44 hepatocellular carcinomas, 23 cholangiocarcinomas, 31 hepatoblastomas, 16 other childhood tumor types (rhabdomyosarcoma, neuroblastoma, Wilms' tumor and rhabdoid tumor), 17 metastatic liver tumors 24 hepatocellular adenomas, 15 high grade dysplastic nodules, 3 biliary cystadenomas, 3 biliary hamartomas and 3 Caroli's diseases. RESULTS: Most of the malignant liver tumors were positive for EZH2, but neither of the adenomas, cirrhotic/dysplastic nodules, reactive and hamartomatous biliary ductules stained positively. CONCLUSIONS: Our immunostainings confirm that EZH2 is a sensitive marker of hepatocellular carcinoma, but its specificity is very low, since almost all the investigated malignant liver tumors were positive regardless of their histogenesis. Based on these results EZH2 is a sensitive marker of malignancy in hepatic tumors. In routine surgical pathology EZH2 could be most helpful to diagnose cholangiocarcinomas, because as far as we know this is the first marker to distinguish transformed and reactive biliary structures. Although hepatoblastomas also express EZH2, the diagnostic significance of this observation seems to be quite limited whereas, the structurally similar, other blastic childhood tumors are also positive. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1173195902735693.
dc.relation.ispartof urn:issn:1746-1596
dc.title Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
dc.type Journal Article
dc.date.updated 2018-06-14T12:39:08Z
dc.language.rfc3066 en
dc.identifier.mtmt 2141973
dc.identifier.wos 000308540700001
dc.identifier.pubmed 22809481
dc.contributor.department SE/AOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet
dc.contributor.department SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.department SE/AOK/I/IISZPI/MTA-SE Molekuláris Onkológia Kutatócsoport
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet